InvestorsHub Logo
Followers 72
Posts 4827
Boards Moderated 0
Alias Born 01/24/2004

Re: entdoc post# 73170

Wednesday, 12/28/2011 10:00:56 PM

Wednesday, December 28, 2011 10:00:56 PM

Post# of 346668
PPHM Corp. Factsheet updated 12-14-11 on the website – includes these updated comments the COTARA program:
http://www.peregrineinc.com/images/stories/pdfs/fact_sheet_12-14-11.pdf

PHASE II COTARA PROMISING SURVIVAL DATA
Our novel single-treatment brain cancer therapy Cotara has demonstrated positive median overall survival data of 9.3 months (40.6 weeks) in a Phase II trial in 41 patients with recurrent glioblastoma multiforme (GBM). To further advance Cotara’s clinical development, we have opened a dialogue with the FDA to determine the critical elements of our pivotal trial protocol, which we expect will support our partnering discussions to advance Cotara’s development.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News